Online PR Dist

Biotage Unveils Isolera Spektra With Full PDA Spectral Scanning

Biotage, a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera Spektra.

 
Repost This

Uppsala, Sweden -- (SBWIRE) -- 04/17/2012 -- Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera™ Spektra. The new Isolera™ Spektra expands the scope of application of Biotage’s market-leading Flash Chromatography product line by increasing efficiency with significant solvent and time saving capabilities as well as enabling purity assessment technology.

The new full PDA spectral scanning capability with ?-All detection and baseline correction generates real-time PDA spectral data for eluting compounds. This provides compound detection at any wavelength, enabling chemists to see how pure their eluting compounds are in both real-time and post-purification. Post-purification spectral analysis can also be conducted in both two dimensional and three dimensional displays for improved visibility of impurities and eliminating the need for post-flash TLC purity testing.

The new proprietary TLC-to-Step gradient feature (patent-pending) instantly converts TLC separation data into an efficient step gradient and suggests a sample load for up to six compounds. Chemists can target one or more compounds for isolation, dramatically reducing solvent requirements and purification time compared to linear gradients. Used in conjunction with Biotage® SNAP Ultra cartridges with their 2-3X loading capacity and flow rate advantage, researchers can routinely achieve total processing times and ultra-low solvent consumption volumes which previously were not possible with other flash instruments.

“Isolera™ Spektra is a revolutionary enhancement in flash purification. It transforms 1-dimensional flash purification into 3D purification systems that can target a specific compound for isolation and characterize collected fractions for purity and spectral properties” says Bob Bickler, Senior Product Manager, Biotage®. “This technology can have a huge positive impact on the amount of time that researchers need to invest in compound purification as well as the solvents they consume. These system improvements combined with high efficiency columns will quickly pay for themselves in any lab”.

For further information visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10.

For further press information at Biotage please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
E-Mail: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 272 employees with sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com